Trulicity

Trulicity

dulaglutide

Manufacturer:

Eli Lilly

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Dulaglutide
Indications/Uses
Type 2 DM as monotherapy in adults inadequately controlled by diet & exercise alone & for whom metformin is inappropriate due to intolerance or contraindication, or as add-on combination therapy w/ glucose-lowering medicinal products (eg, insulin) when together w/ diet & exercise is inadequate. Reduces risk of major adverse CV events (eg, CV death, non-fatal MI or stroke) in adults w/ type 2 DM who have multiple CV risk factors w/ or w/o established CV disease.
Dosage/Direction for Use
SC Monotherapy 0.75 mg once wkly. Add-on therapy 1.5 mg once wkly. Potentially vulnerable population (eg, ≥75 yr patient) Initially 0.75 mg once wkly.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Discontinue use if pancreatitis is suspected & not to be restarted if pancreatitis is confirmed. Not to be administered IV or IM. Not to be used in patients w/ type 1 DM or for treatment of diabetic ketoacidosis. Not a substitute for insulin. Not recommended for patients w/ severe GI disease including severe gastroparesis. Dehydration; acute pancreatitis; increased risk of hypoglycaemia. Patients w/ CHF. Monitor patients w/ history of diabetic retinopathy for progression. May cause deterioration of renal function including acute renal failure in patients w/ impaired renal function. May affect ability to drive or use machines when used in combination w/ sulphonylurea or insulin. Not recommended in patients w/ ESRD (estimated GFR <15 mL/min/1.73 m2). Not recommended during pregnancy. Not to be used during lactation. Childn <18 yr.
Adverse Reactions
Hypoglycaemia; nausea, diarrhoea, vomiting, abdominal pain. Decreased appetite, dyspepsia, constipation, flatulence, abdominal distention, GERD, eructation; fatigue; sinus tachycardia, 1st degree AV block.
Drug Interactions
Delayed gastric emptying & affected absorption rate w/ oral medicinal products requiring rapid GI absorption. Increased exposure, Cmax & tmax w/ sitagliptin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BJ05 - dulaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Trulicity soln for inj 0.75 mg/0.5 mL
Packing/Price
4 × 1's
Form
Trulicity soln for inj 1.5 mg/0.5 mL
Packing/Price
4 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in